Most importantly, the anti–IL-18–pretreated cerulein-plus-AOM–treated mice showed significantly reduced EPX-positive eosinophils with highly improved ADM compared with cerulein-plus-AOM–treated mice without anti–IL-18 (Fig 5Ci–v). The gene discussed is IL18; the disease is infectious otitis media.